鏈接：https://www.abinscience.cn/product/34/55906.html

名稱：Anti-LY3437943 Polyclonal Antibody

貨號：HW328024

種屬反應(yīng)性：General

應(yīng)用：ELISA, IHC, WB

宿主：Rabbit

同種型：IgG

克隆類型：Polyclonal

免疫原：LY3437943

靶標(biāo)：LY3437943, LY-3437943, CAS: 2381089-83-2

內(nèi)毒素水平：Please contact with the lab for this information.

純化方式：Purified by antigen affinity column.

狀態(tài)：Liquid

用途范圍：僅用于科研

儲存：Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

?

產(chǎn)品介紹：Anti-LY3437943 Polyclonal Antibody (HW328024) 是艾必賽生物（abinScience）推出的兔源多克隆抗體（兔 IgG），靶向 LY3437943（即 Retatrutide，禮來在研 GLP-1R/GIPR/GCGR 三靶點(diǎn)激動劑多肽），可作為Retatrutide 相關(guān)藥物開發(fā)、PK/ADA 方法建立、ELISA/WB/IHC 檢測的對照/捕獲工具。該抗體以 LY3437943 為免疫原，經(jīng)抗原親和柱純化，以液體形式保存在 0.01M PBS, pH 7.4，含 50% 甘油 + 0.05% Proclin 300 中；頻繁使用 2–8°C，長期建議 -20 至 -80°C 避反復(fù)凍融（自收貨日起 ≤12 個(gè)月）。（RUO，僅限科研/非臨床用途）

LY3437943（Retatrutide）是禮來開發(fā)的胰高血糖素樣肽-1 受體（GLP-1R）/葡萄糖依賴性促胰島素多肽受體（GIPR）/胰高血糖素受體（GCGR）三激動劑，通過同時(shí)激活三條代謝通路協(xié)同調(diào)控食欲、能量消耗與糖脂代謝，目前 III 期臨床數(shù)據(jù)顯示其減重與降糖效力優(yōu)于替爾泊肽（Tirzepatide），被視為下一代代謝疾病重磅分子。作為多肽類藥物，Retatrutide 的血藥濃度監(jiān)測（PK）、免疫原性（ADA）評估及作用機(jī)制研究均需高特異性抗藥抗體/檢測抗體支撐，HW328024 以全-length 多肽免疫、親和純化獲得，適合用于 ELISA（1:2000–1:20000）、WB（1:500–1:2000）、IHC 等方法搭建，是 Retatrutide 臨床前與轉(zhuǎn)化研究中配套的科研級試劑。

?

?

?

?

產(chǎn)品購買聯(lián)系方式：027-87433958/17302791434

郵箱：info@abinscience.com

參考文獻(xiàn)：

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. PMID: 38843460

Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. PMID: 39212900

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. PMID: 39019866

The First Triple Agonist for Antiobesity: Retatrutide. PMID: 39724554

Emerging pharmacotherapies for obesity: A systematic review. PMID: 39952695

Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? PMID: 38687506

What is the pipeline for future medications for obesity? PMID: 38302593

Gut hormones and appetite regulation. PMID: 38511400

Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge. PMID: 41056349

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. PMID: 39761578

Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis. PMID: 41537067

The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities. PMID: 41545327

Retatrutide And Lipid And Metabolite Profiles In Participants With Obesity With Or Without Type 2 Diabetes. PMID: 42135195

Weight management treatment in obesity. PMID: 40865172

Triple Agonism Based Therapies for Obesity. PMID: 40741227

The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. PMID: 39481534

Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis. PMID: 39817343

Triple-Hormone-Receptor Agonist Retatrutide for Obesity. PMID: 37888925

Retatrutide: a triple incretin receptor agonist for obesity management. PMID: 37902090

Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases. PMID: 39096466

Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids. PMID: 40726454

Contractile effects of retatrutide in isolated mouse atrial preparations. PMID: 40464942

Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials. PMID: 38976545

Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. PMID: 41054801

The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. PMID: 40630318

Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? PMID: 37086147

Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions. PMID: 38681750

The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. PMID: 40022548

Triple-Hormone Combination Retatrutide Induces 24% Body Weight Loss. PMID: 37405802

Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. PMID: 41741376

Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. PMID: 39305981

Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. PMID: 41216380

Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP. PMID: 39868848

?

?

詳情請咨詢 abinScience 亞洲區(qū)官方子公司 —— 武漢艾必賽生物技術(shù)有限公司

官方網(wǎng)址：【中文】https://www.abinscience.cn

【英文】https://www.abinscience.com

武漢艾必賽生物技術(shù)有限公司成立于 2023 年，是 abinScience 在亞洲地區(qū)設(shè)立的官方全資子公司，全面負(fù)責(zé) abinScience 品牌在亞太市場的科研試劑推廣、銷售及技術(shù)支持工作。

依托嚴(yán)格的產(chǎn)品研發(fā)體系和國際化的質(zhì)量管理標(biāo)準(zhǔn)，武漢艾必賽與 AtaGenix、ProteoGenix 等知名品牌保持長期戰(zhàn)略合作，現(xiàn)已構(gòu)建起涵蓋抗體、重組蛋白、工具酶、試劑盒、實(shí)驗(yàn)耗材在內(nèi)的多品類供應(yīng)體系，面向區(qū)域內(nèi)科研機(jī)構(gòu)、高校實(shí)驗(yàn)室與生物醫(yī)藥企業(yè)，提供穩(wěn)定、高效、可信賴的產(chǎn)品與服務(wù)。

核心業(yè)務(wù)覆蓋：
? 抗體產(chǎn)品（單抗、多抗、重組抗體等）
? 蛋白與多肽試劑（標(biāo)簽蛋白、功能蛋白等）
? 分子與細(xì)胞實(shí)驗(yàn)相關(guān)耗材
? 定制化研發(fā)服務(wù)（蛋白表達(dá)、抗體定制、親和力成熟等）
? 科研供應(yīng)鏈整合與項(xiàng)目配套支持

武漢艾必賽始終秉持“Empowering Bioscience Discovery”的理念，為亞太地區(qū)的生命科學(xué)研究持續(xù)注入高質(zhì)量動能。

?

?